3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Hepatocellular
20
Carcinoma, Renal Cell
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Endometrial Neoplasms
7
Neoplasms
4
Biliary Tract Neoplasms
4
Uterine Cervical Neoplasms
3
Neuroendocrine Tumors
3
Melanoma
3
Liver Neoplasms
3
Vulvar Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
von Hippel-Lindau Disease
1
Thyroid Carcinoma, Anaplastic
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Penile Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lung Neoplasms
1
Kidney Neoplasms
1
Interventions
tremelimumab
2
pembrolizumab
2
Nivolumab
2
Carboplatin
2
poly ICLC
1
osimertinib
1
lenvatinib
1
durvalumab
1
cemiplimab
1
balstilimab
1
Vascular Endothelial Growth Factor A
1
Peptides
1
Pemetrexed
1
Paclitaxel
1
Ipilimumab
1
Docetaxel
1
Blood Specimen Collection
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
lenvatinib
×
90 days
×
Clear all
NCT04305054
2026-05-28
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2
Completed
335 enrolled